Sun Pharma posts profit above forecasts but margin erosion weighs on shares
Sun Pharmaceutical Industries reported a March-quarter net profit slightly above analyst expectations, driven by growth in its specialty therapies franchise. However, rising costs - notably in research and development - pushed expenses sharply higher and compressed core margins, prompting a drop in the company's share price despite the profit beat.